The findings about the link between HIET, AMPK/SREBP/PPARα, and hepatic lipid metabolism may be helpful for the development of a novel adjuvant therapy to achieve better control of NAFLD and improve the lives of the patient population. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.